Abstract
Cell adhesion molecules (CAMs) are transmembrane proteins that mediate adhesion and interactions between cells or cell and extra-cellular matrix. Increased expression and activation of CAMs in vascular endothelial cells and circulating leukocytes, as occurring in the settings of inflammation, hypercholesterolemia, hypertension and diabetes, stimulates leukocyte recruitment into the vascular endothelium, an important step in the pathogenesis of atherosclerosis. CAMs are a potential therapeutic target in clinical practice and in recent years pharmaceutical agents with specific effects on the production and function of these molecules have been studied and developed. This article reviews recent progress regarding pathophysiology of CAMs in atherogenesis and pharmaceutical products or chemicals that are active against CAMs, and assesses the possibilities for clinical developments in this area that might enhance the prevention, monitoring and treatment of atherosclerotic cardiovascular diseases.
Keywords: Atherosclerosis, cell adhesion molecules, leukocyte recruitment, vascular endothelium, pharmaceutical therapy, glycoproteins, in vitro, aortic, leukocytes, transmembrane
Mini-Reviews in Medicinal Chemistry
Title: Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis
Volume: 12 Issue: 2
Author(s): S. Ling, L. Nheu and P. A. Komesaroff
Affiliation:
Keywords: Atherosclerosis, cell adhesion molecules, leukocyte recruitment, vascular endothelium, pharmaceutical therapy, glycoproteins, in vitro, aortic, leukocytes, transmembrane
Abstract: Cell adhesion molecules (CAMs) are transmembrane proteins that mediate adhesion and interactions between cells or cell and extra-cellular matrix. Increased expression and activation of CAMs in vascular endothelial cells and circulating leukocytes, as occurring in the settings of inflammation, hypercholesterolemia, hypertension and diabetes, stimulates leukocyte recruitment into the vascular endothelium, an important step in the pathogenesis of atherosclerosis. CAMs are a potential therapeutic target in clinical practice and in recent years pharmaceutical agents with specific effects on the production and function of these molecules have been studied and developed. This article reviews recent progress regarding pathophysiology of CAMs in atherogenesis and pharmaceutical products or chemicals that are active against CAMs, and assesses the possibilities for clinical developments in this area that might enhance the prevention, monitoring and treatment of atherosclerotic cardiovascular diseases.
Export Options
About this article
Cite this article as:
Ling S., Nheu L. and A. Komesaroff P., Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis, Mini-Reviews in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/138955712798995057
DOI https://dx.doi.org/10.2174/138955712798995057 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of NLRP-3 Inflammasome in Hypertension: A Potential Therapeutic Target
Current Pharmaceutical Biotechnology Reduced Hemoglobin Levels Combined with an Increased Plasma Concentration of Vasoconstrictive endothelin-1 are Strongly Associated with Poor Outcome During Acute Ischemic Stroke
Current Neurovascular Research Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis: An Uncommon Yet Important Complication
Current Rheumatology Reviews Immunophilins are Involved in the Altered Platelet Aggregation Observed in Patients with Type 2 Diabetes Mellitus
Current Medicinal Chemistry Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews Pharmacogenomics
Current Drug Metabolism Protein Kinase C Inhibitors in the Treatment of Diabetic Retinopathy. Review
Current Pharmaceutical Biotechnology Utility of Intrapartum Transabdominal Ultrasound for the Correct Placement of Vacuum during Assisted Delivery
Current Women`s Health Reviews Development and Validation of a New Method to Quantify Pilocarpine in Tablets by HPLC-DAD
Current Pharmaceutical Analysis Drug Metabolism and Transport Under Hypoxia
Current Drug Metabolism Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana
Current Pharmaceutical Design Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial
Current Gene Therapy Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis
Recent Patents on Drug Delivery & Formulation Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?
Current Vascular Pharmacology From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design